Core Viewpoint - The article discusses the recent challenges faced by Taiji Group, including regulatory issues related to drug production and quality management, as well as its performance in the ESG (Environmental, Social, and Governance) report for 2024 [4][6][10]. Group 1: Company Overview - Taiji Group focuses on the manufacturing of traditional Chinese and Western medicines, operating 13 pharmaceutical factories and over 20 pharmaceutical commercial companies, making it one of the most complete companies in the domestic pharmaceutical industry [3]. - The company holds a 74.65% stake in its subsidiary, Sichuan Taiji Pharmaceutical, which has recently faced regulatory scrutiny [5]. Group 2: Regulatory Issues - Sichuan Taiji Pharmaceutical was placed on a "violation list" and suspended from participating in national drug procurement activities for 18 months due to non-compliance with Good Manufacturing Practice (GMP) standards [4]. - The company has been criticized for not effectively monitoring its subcontracted production processes, leading to quality management failures [4][5]. Group 3: ESG Report Insights - In its 2024 ESG report, Taiji Group identified "product quality and safety" as the most critical issue for both the company and its stakeholders [6]. - The company reported that nearly 20% of its 2,853 suppliers are certified under the ISO 9001 quality management system [6]. Group 4: Financial Performance - For the year 2024, Taiji Group achieved a revenue of 12.386 billion yuan, a 20% decline compared to the previous year, with a net profit of 27 million yuan, down 96.76% after tax adjustments [13]. Group 5: Environmental Performance - Taiji Group's carbon emissions totaled 113,000 tons of CO2 equivalent in 2024, a reduction of 45.65% from the previous year, with a significant decrease in emissions intensity per million yuan of revenue [12]. - The company has implemented a comprehensive energy management system and upgraded equipment to enhance efficiency and reduce energy waste [13].